Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells

American Journal of Clinical Pathology

Volumn 127, Issue 5, 2007, Pages 752-759

  Davidson, Ben ^a,b   Hiep, Phuc Dong ^a   Holth, Arild ^a   Berner, Aasmund ^a   Risberg, Björn ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemokine receptors; Effusions; Immune response; Malignant mesothelioma; Reactive mesothelium

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR4;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; AUTOCRINE EFFECT; BENIGN TUMOR; CELL INFILTRATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM; MESOTHELIUM CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ASCITES FLUID; EPITHELIUM CELL; IMMUNOLOGY; LEUKOCYTE; MESOTHELIOMA; MIDDLE AGED; PLEURA EFFUSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; EPITHELIAL CELLS; FEMALE; HUMANS; LEUKOCYTES; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL EFFUSION; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4; RECEPTORS, INTERLEUKIN-8A;

EID: 34249701820     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/LN2075V7C8K31CH8     Document Type: Article

References (17)

1. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res. 2001;264:169-184.
2. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263-266.
3. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605-612.
4. Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol. 2002;12:113-120.
5. Homey B, Müller A, Zlotnik A. Chemokines: agents for immunotherapy of cancer. Nat Rev Immunol. 2002;2:175-184.
6. Britton M. The epidemiology of mesothelioma. Semin Oncol. 2002;29:18-25.
7. Bedrossian CWM. Diagnostic problems in serous effusions. Diagn Cytopathol. 1998;19:131-137.
8. Davidson B, Vintman L, Zcharia E, et al. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis. 2004;21:469-476.
9. Galffy G, Mohammed KA, Dowling PA, et al. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res. 1999;59:367-371.
10. Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res. 1999;5:3364-3368.
11. Hegmans JP, Hemmes A, Hammad H, et al. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 2006;27:1086-1095.
12. DeLong P, Carroll RG, Henry AC, et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther. 2005;4:342-346.
13. Kleinberg L, Flørenes VA, Skrede M, et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 2006;449:31-39.
14. Dong HP, Bunkholt Elstrand M, Holth A, et al. NK and B cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol. 2006;125:451-458.
15. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001;25:1405-1412.
16. Davidson B, Dong HP, Berner A, et al. Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. Am J Clin Pathol. 2002;118:85-92.
17. Risberg B, Davidson B, Nielsen S, et al. Detection of monocyte/macrophage cell populations in effusions: a comparative study using flow cytometric immunophenotyping and immunocytochemistry. Diagn Cytopathol. 2001;25:214-219.